With the increasing focus on early-stage cancer screening, research communities and the companies involved in the field of microbiome sequencing are significantly investing in expanding their respective product and service mix.
As of 2020, the global cancer microbiome sequencing market, by application, was dominated by translational research, holding a 76.78% market share. During the forecast period of 2021-2031, while the change may be positive for the diagnostics application and negative for the translational research, the overall market share will still be dominated by the later with the segment anticipated to hold a 74.18% share in 2031.
This continuous popularity in demand is majorly due to the increase in developmental research for commercializing products in the market, growing focus on establishing precision medicine in the field of clinical oncology, and increasing fund infusions by the governments worldwide, among others.
Key Questions Answered in this Report:
• How is cancer microbiome sequencing revolutionizing the field of oncology?
• What are the major market drivers, challenges, and opportunities in the global cancer microbiome sequencing market?
• What are the underlying structures resulting in the emerging trends within the global cancer microbiome sequencing market?
• How did the COVID-19 pandemic impact the global cancer microbiome sequencing ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of cancer microbiome sequencing?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Offering (product and service)
o Application (translational research and diagnostics)
o Technology (next-generation sequencing and polymerase chain reaction)
o End User (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the cancer microbiome sequencing companies in the region of their operation?
• Who are the leading players with significant offerings in the global cancer microbiome sequencing market?
• Which companies are anticipated to be highly disruptive in the future, and why?
No comments:
Post a Comment